GHRP-6 5mg

GHRP-6 is a growth hormone releasing peptide designed for research and experimental use. This 5mg formulation supports investigation into growth hormone secretion pathways and metabolic processes. Ideal for qualified researchers and laboratories exploring peptide mechanisms in controlled settings. Each vial contains precisely measured GHRP-6 for consistent experimental protocols.

Specification Peptide: GHRP-6 (Growth Hormone Releasing Peptide-6) Quantity: 5mg per vial Purity: Research grade Form: Lyophilized powder Intended Use: Laboratory and research applications only Storage: Keep in cool, dry conditions away from direct light Reconstitution: Compatible with sterile bacteriostatic water or saline solution

Molecular Formula: C40H69N15O10 Molecular Weight: 873.07 g/mol Structure: Hexapeptide Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 CAS Number: 87616-84-0 Classification: Research peptide, growth hormone secretagogue

Storage Before Reconstitution Store lyophilized GHRP-6 vials at 2–8°C (refrigerated) or at room temperature (15–25°C) in a cool, dry place away from direct sunlight and moisture. Properly sealed vials maintain stability for extended periods under these conditions. Keep away from heat sources and humidity. Storage After Reconstitution Once reconstituted with sterile bacteriostatic water or saline solution, store the solution at 2–8°C (refrigerated). Reconstituted peptide solutions typically remain stable for 2–4 weeks when stored properly in sterile conditions. Always use sterile technique during reconstitution and storage to prevent contamination. Do not freeze reconstituted solutions unless specifically required for your research protocol.

Research References

The following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.

1. GHRP-6: Discovery and GH-Releasing Activity
   Bowers CY, et al. (1991). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology, 128(4), 2027–2035. https://doi.org/10.1210/endo-128-4-2027
   Foundational study characterising GHRP-6 as a potent synthetic hexapeptide GH secretagogue, demonstrating dose-dependent GH release from pituitary somatotrophs both in vitro and in vivo, and establishing its pharmacological profile as distinct from GHRH.
2. GHRP-6 and the Ghrelin Receptor (GHS-R1a)
   Howard AD, et al. (1996). A receptor in pituitary and hypothalamus that functions in growth hormone release. Science, 273(5277), 974–977. https://doi.org/10.1126/science.273.5277.974
   Reports the cloning and characterisation of the growth hormone secretagogue receptor (GHS-R1a) — the primary molecular target of GHRP-6 — establishing the receptor biology underpinning all GHRP research and its relationship to the endogenous ghrelin system.
3. GHRP-6 Synergy with GHRH in GH Secretion
   Pandya N, et al. (1998). Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. Journal of Clinical Endocrinology & Metabolism, 83(4), 1186–1189. https://doi.org/10.1210/jcem.83.4.4716
   Demonstrates that GHRP-6’s maximal GH-releasing effect requires intact endogenous GHRH signalling, establishing the synergistic relationship between GHS-R1a agonism and GHRH receptor activation — key context for combination peptide research protocols.
4. GHRP-6 and Ghrelin: Appetite and Metabolic Regulation
   Kojima M, et al. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 402(6762), 656–660. https://doi.org/10.1038/45230
   The landmark paper identifying ghrelin as the endogenous ligand for GHS-R1a — the same receptor activated by GHRP-6 — establishing the mechanistic link between GHRP-6 activity, appetite stimulation, and metabolic regulation that underpins its orexigenic effects in research models.
5. GHRP-6 Cardioprotective Effects in Ischaemia Models
   Granado M, et al. (2006). Ghrelin and growth hormone secretagogues protect cardiomyocytes from ischemia-reperfusion injury. Endocrinology, 147(9), 4484–4492. https://doi.org/10.1210/en.2006-0291
   Demonstrates that GHRP-6 and related GHS-R1a agonists exert direct cardioprotective effects in rat cardiomyocyte ischaemia-reperfusion models, independent of GH release, via anti-apoptotic and anti-inflammatory signalling — expanding the research scope of GHRP-6 beyond the GH axis.

All references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.